Hepatorenal syndrome - acute kidney injury (HRS-AKI)
HRS, hepatorenal syndrome, HRS-AKI, terlipressin, albumin, cirrhosis AKI · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Functional, potentially reversible AKI in advanced cirrhosis with ascites (or acute liver failure), driven by splanchnic vasodilation and renal vasoconstriction, with no structural kidney injury. A diagnosis of exclusion after volume expansion and withdrawal of diuretics/nephrotoxins fail. High mortality; treated with a vasoconstrictor (terlipressin) plus albumin, with transplant the definitive option.
Red flags
- Rapidly rising creatinine with oliguria and refractory ascites
- Terlipressin ischaemic complications (mesenteric/digital/myocardial) or respiratory failure/pulmonary oedema
- Untreated SBP or sepsis
- GI/variceal bleeding as precipitant
- Hyperkalaemia / fluid overload / severe acidosis requiring RRT
- Progression despite therapy - transplant window
Assessment
Differential diagnosis
- Pre-renal AKI / hypovolaemia (GI bleed, diuretics, diarrhoea, large-volume paracentesis without albumin)
- Acute tubular necrosis (sepsis, nephrotoxins, contrast)
- Spontaneous bacterial peritonitis-induced AKI
- Drug-induced (NSAIDs, aminoglycosides, contrast)
- Post-renal obstruction
- Glomerular disease (IgA, HCV cryoglobulinaemia) - check urine/protein/casts
Investigations
- Serial serum creatinine (ICA-AKI criteria: rise >=26.5 micromol/L in 48h or >=50% in 7 days); baseline creatinine
- Urinalysis/microscopy (bland sediment in HRS), urine protein, renal USS (exclude obstruction, structural disease)
- Diagnostic ascitic tap: cell count and culture to EXCLUDE SBP (common precipitant) in all cirrhotic AKI
- Septic screen (cultures, CXR, urine); FBC, U&E, LFTs, INR, lactate
- Urinary sodium / fractional excretion of sodium (low in HRS, non-specific); urine NGAL where available to help distinguish ATN
- Review drug chart (diuretics, NSAIDs, nephrotoxins, recent large-volume paracentesis, contrast)
Management
- Treat as cirrhotic AKI: stop diuretics, beta-blockers (if hypotensive), NSAIDs and all nephrotoxins; stop/avoid nephrotoxic contrast
- Screen for and treat precipitants - especially SBP (diagnostic tap) and GI bleeding/sepsis; give antibiotics for infection
- VOLUME CHALLENGE: expand plasma with IV albumin 1 g/kg/day (max ~100 g/day) for 2 days and withhold diuretics - if creatinine does not improve and other causes excluded, diagnose HRS-AKI
- Start vasoconstrictor + albumin: terlipressin plus daily IV albumin (first-line) - titrate to improvement in creatinine and MAP
- In ICU, noradrenaline + albumin is an alternative vasoconstrictor where terlipressin unavailable/contraindicated
- Monitor for terlipressin adverse effects: ischaemia (mesenteric, digital, cardiac) and RESPIRATORY failure/volume overload - watch fluid balance and oxygenation
- Assess response (creatinine); continue up to ~14 days if responding; manage refractory cases with renal replacement therapy as a bridge
- Refer urgently for LIVER TRANSPLANT assessment - definitive treatment; HRS often recurs without it
Drugs & doses
Human albumin solution (20%) 1 g/kg/day IV (max ~100 g/day) for the initial 2-day volume challenge, then daily albumin (~20-40 g/day) alongside vasoconstrictor
Terlipressin 0.5-1 mg IV every 4-6 h (or continuous infusion 2-12 mg/24h), titrated up if no response, to a max per local protocol, continued up to 14 days - WITH albumin [verify local dose]
Noradrenaline (ICU alternative) 0.5-3 mg/h IV infusion titrated to raise MAP by ~10 mmHg, with albumin - where terlipressin unavailable/contraindicated
Midodrine + octreotide + albumin as a less effective alternative where terlipressin/noradrenaline not available [verify local]
Antibiotics for SBP/sepsis (e.g. IV third-generation cephalosporin for SBP) plus albumin 1.5 g/kg day 1 and 1 g/kg day 3 for SBP to prevent HRS
STOP diuretics, NSAIDs, nephrotoxins, and nephrotoxic contrast
Renal replacement therapy as a bridge to transplant/recovery in refractory cases
Disposition
Admit, usually HDU/ICU. Hepatology + nephrology. Urgent liver transplant assessment. RRT as bridge in selected refractory/transplant-candidate patients.
Complications & pitfalls
- Progression to dialysis-dependent renal failure and death
- Terlipressin-related ischaemia and respiratory failure (14% in CONFIRM vs 5% placebo)
- Fluid overload/pulmonary oedema from albumin loading
- Recurrence of HRS after initial response
- Multi-organ failure / acute-on-chronic liver failure
Exam pearls
- HRS-AKI is a diagnosis of EXCLUSION: it requires AKI meeting ICA criteria, no response to 2 days of diuretic withdrawal + albumin 1 g/kg/day, and exclusion of shock, nephrotoxins and structural/parenchymal kidney disease.
- Terlipressin PLUS albumin is first-line (AASLD 2021/EASL; CONFIRM trial, FDA-approved 2022) - reversal ~32% vs 17% placebo; watch for RESPIRATORY FAILURE (14%) and ischaemia, and avoid over-loading albumin.
- Always do a diagnostic ascitic tap to exclude SBP in any cirrhotic patient with AKI - and give albumin 1.5 g/kg (day 1) + 1 g/kg (day 3) in SBP to prevent HRS.
- Noradrenaline + albumin in ICU is a reasonable alternative to terlipressin; midodrine/octreotide is less effective.
- The only definitive treatment is LIVER TRANSPLANT - refer early, as HRS frequently recurs and mortality is very high without it. Terlipressin dosing/duration [verify local protocol].
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.